SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IGEN International -- Ignore unavailable to you. Want to Upgrade?


To: chalu2 who wrote (507)9/8/1999 12:37:00 PM
From: jpbrody  Read Replies (1) | Respond to of 1025
 
chalu, what I meant by the buyout price was the value of the contract with Roche. Since IGEN has other business besides the Roche contract, the share price would certainly be higher than what Roche pays to buy out the contract. A buyout number of $50/share would probably lead to a share price greater than $50/share, but less than a $50 increase over the current price (because some value of the contract is probably built into the current price.)

Jim